Company details

Targovax ASA

  • Print
  • Share Share
no en

Targovax is an Oslo and Helsinki-based immune oncology company, dedicated to the design, development and commercialization of targeted immunotherapy vaccines for patients with solid tumors. Vaccines for RAS-mutated cancer and vaccines based on engineered oncolytic viruses armed with potent immune-stimulating transgenes are in development. The two platforms are aimed at providing a unique treatment of several cancer types such as pancreatic cancer, malignant melanoma, colorectal cancer, soft tissue sarcoma, prostate cancer, ovarian cancer and malignant mesothelioma. Targovax has Orphan Drug Designation with the FDA and EMA for TG01 in pancreatic cancer and ONCOS-102 in malignant plural mesothelioma, ovarian cancer and soft tissue sarcoma.